The global biobanking market is projected to reach around US$53 billion by 2027, expanding at a growth rate of approximately 8%. Market growth is driven by rapid advancements in genomic research, a rising incidence of chronic diseases such as cancer, Alzheimer’s, and cardiovascular disorders, and the growing emphasis on personalized medicine. Additionally, increasing demand for efficient drug discovery and development, advancements in regenerative medicine and cell therapy, growing awareness regarding the preservation of newborn cord blood stem cells, and strong private and government investments toward biobank establishment and expansion are fueling the market’s momentum.
Request Sample Pages: https://meditechinsights.com/biobanking-market/request-sample/
Biobanks are specialized facilities responsible for collecting, storing, and managing biological specimens such as human tissues, fluids, and genetic materials under controlled environments. These samples serve as essential resources for medical research, diagnostics, and therapeutic development. Biobanks can be broadly categorized into population-based and disease-oriented repositories. Population-based biobanks collect samples from the general population to study genetic predispositions and the impact of environmental factors, whereas disease-oriented biobanks focus on disease-specific specimens to facilitate targeted research in areas such as oncology or cardiovascular science.
A key trend shaping the biobanking industry is the increasing use of automation and digital solutions to safeguard biological samples. Automation technologies, including robotics, AI-driven systems, and advanced data analytics, are revolutionizing the way samples are stored, retrieved, and managed. Automated systems not only ensure sample integrity and minimize contamination risks but also reduce manual handling errors through automated barcode tracking and workflow management. They further enhance operational efficiency by integrating laboratory information management systems (LIMS) and optimizing liquid handling and storage processes, allowing researchers to focus on high-value analytical activities.
The growing reliance on biobanks for research purposes is significantly accelerating market growth. Biobanks serve as invaluable resources for biomedical research, enabling scientists to safely store and access high-quality biological samples for extended periods without compromising their integrity. This facilitates the study of disease mechanisms, biomarker discovery, and the development of personalized treatments. Moreover, biobanks enable collaboration across institutions and enhance data sharing, expediting drug discovery and translational research. An example of innovation in this domain includes the 2023 initiative by the Biobanking and Biomolecular Resources Research Infrastructure – European Research Infrastructure Consortium (BBMRI-ERIC), which launched the Innovative Federated Platform Finder and Locator to improve global accessibility to biobank resources.
Biobanking is also contributing to sustainability and environmental goals. By storing samples for long-term research use, biobanks reduce the need for redundant testing and animal experimentation. Modern biobanking facilities increasingly adopt energy-efficient cryopreservation systems and automation technologies that minimize energy consumption, reduce biological waste, and promote sustainable scientific practices.
The COVID-19 pandemic had a positive impact on the biobanking market. Biobanks played a critical role in supporting global research efforts by preserving and providing access to COVID-19 specimens necessary for diagnostic, therapeutic, and vaccine development. Collaborative efforts among government, academia, and industry highlighted the indispensable role of biobanks in advancing pandemic-related research and innovation.
However, several challenges continue to hinder market expansion. These include the lack of standardized workflows and data harmonization across biobanks, interoperability issues among IT platforms, difficulties in maintaining sample quality and integrity, and concerns around data privacy and ethical regulations. Furthermore, variations in legal frameworks and limited willingness among researchers to share biological materials pose additional constraints.
Regionally, Europe dominates the global biobanking market, driven by the presence of advanced biobank infrastructures, strong government and private funding, and increasing adoption of innovative storage technologies. North America also represents a significant share, supported by large-scale biobanking networks, intensive R&D investments, and stringent quality standards. The Asia-Pacific region is anticipated to record the fastest growth due to a rising burden of chronic diseases, technological progress in automation, and greater awareness of precision medicine initiatives.
The competitive landscape of the biobanking market features major players such as Thermo Fisher Scientific Inc., Tecan Trading AG, QIAGEN, Hamilton Company, Azenta Life Sciences, STEMCELL Technologies Inc., PrecisionMed (BioIVT Company), BioLife Solutions Inc., BioRep S.r.l., Cryo-Cell International, Biogen, Taylor-Wharton, and BioIVT & Elevating Science. Companies in this sector are actively pursuing both organic and inorganic growth strategies, including product innovation, partnerships, and acquisitions. Notable examples include the November 2023 release by UK Biobank of comprehensive whole-genome sequencing data from half a million participants and BioLife Solutions’ launch of its ISO-certified, energy-efficient ULT freezers for sustainable biobanking operations.
Key Request a free sample copy or view report summary : https://meditechinsights.com/biobanking-market/request-sample/
With ongoing technological advancements, rising investments in biobanking infrastructure, and the growing integration of digital and automated systems, the global biobanking market is poised for steady expansion. The sector’s evolution will continue to support groundbreaking biomedical research, precision medicine, and sustainable scientific practices, reinforcing biobanks as critical assets in the future of healthcare and life sciences.
About Medi-Tech Insights
Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services in the areas of market assessments, due diligence, competitive intelligence, market sizing and forecasting, pricing analysis & go-to-market strategy. Our methodology includes rigorous secondary research combined with deep-dive interviews with industry-leading CXO, VPs, and key demand/supply side decision-makers.
Contact:
Ruta Halde
Associate, Medi-Tech Insights
+32 498 86 80 79
info@meditechinsights.com
